An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib in Patients With Recurrent Ovarian Cancer or Triple Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Fluzoparib (Primary) ; Rivoceranib (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 31 Aug 2018 Biomarkers information updated
- 23 Mar 2017 Status changed from not yet recruiting to recruiting.
- 14 Mar 2017 New trial record